Agenus Inks $141M Cancer Deal
Agenus, which has research operations in Maryland, has closed a $141 million collaboration with India's Zydus Lifesciences. The partnership will focus on developing and commercializing new cancer immunotherapies, reinforcing Maryland's position as a global biotech hub.
The core of the Agenus-Zydus deal centers on Agenus's two-drug immunotherapy combination, botensilimab (BOT) and balstilimab (BAL). This therapy is aimed at cancers that have traditionally been resistant to immunotherapy, such as certain types of colorectal cancer. The collaboration is designed to accelerate the global development and commercialization of this promising BOT+BAL program. The $141 million agreement is structured in three parts: a $75 million upfront payment for manufacturing facilities, a $16 million equity investment by Zydus in Agenus, and up to $50 million in future milestone payments based on production orders. As part of the deal, Zydus now owns two of Agenus's biologics manufacturing plants in Emeryville and Berkeley, California. This move provides Agenus with significant capital and secures long-term U.S.-based manufacturing capacity without the operational costs of running the facilities. For Zydus, an established Indian pharmaceutical company with over 27,000 employees, the deal provides a strategic entry into the U.S. biologics manufacturing market through a new subsidiary, Zylidac Bio LLC. While Agenus is headquartered in Lexington, Massachusetts, this major deal highlights the interconnected nature of the national life sciences industry. The partnership leverages biomanufacturing on the West Coast to advance therapies that could one day be used in healthcare systems nationwide, including in Maryland's robust BioHealth Capital Region. The BioHealth Capital Region, which includes Maryland, has been consistently ranked as a top 3 U.S. biopharma cluster by Genetic Engineering & Biotechnology News. The region is a national leader in biotechnology-related patents and is third in the country for both NIH funding and the amount of laboratory space. This strong local ecosystem is home to major players like AstraZeneca, which is investing $300 million in a Rockville cell therapy facility, and hundreds of other life sciences companies. Such a high concentration of research, funding, and talent creates significant career and economic opportunities for professionals in the Fort Washington area and across the state.
